A practical evaluation framework for pharma directors assessing medcomms agency capabilities, compliance infrastructure, and KOL network depth before committing to a launch partner.
Executive Summary (TL;DR)
The Evaluation Gap: Most pharma companies assess medcomms agencies on credentials alone — missing the criteria that actually predict launch performance in India.
The Differentiating Criteria: Therapy area depth, active KOL (Key Opinion Leader) network quality, and embedded compliance infrastructure separate capable agencies from credible-looking ones.
The Strategic Imperative: Companies that run structured agency assessments before shortlisting consistently close the gap between pre-launch intent and commercial outcomes.
Pharma & Life Sciences Practice • Brand Strategy Intelligence
Fig 1. A structured agency evaluation shows if a medcomms partner can turn scientific strategy into measurable launch results in India.
India’s pharmaceutical market operates on a different logic than any other. When a pharma company selects a medical communications agency in India, that decision directly shapes how scientific narratives reach prescribers, payers, and patient communities. Regulatory timelines, HCP engagement norms, and KOL ecosystems all carry local dimensions that agencies operating on global templates routinely underestimate.
The brief most pharma directors bring to a medical communications agency selection is often under-scoped. Scientific communication capability matters, but so does the pharma brand strategy infrastructure — the commercial intelligence, the launch messaging architecture, and the prescriber engagement model that turns regulatory approval into measurable market uptake. Separating these two mandates at agency selection leads to fragmented execution at launch.
OneAlphaMed works across both disciplines. In OneAlphaMed’s evaluation work across Indian pharma launches, the agencies that consistently delivered on-brief shared five measurable characteristics. The criteria most companies apply — credentials, case study portfolios, client lists — measure history, not current capability. What follows identifies each criterion and the questions to ask before shortlisting.
India presents a medcomms environment that rewards specificity above all else. The country spans more than 600 districts, each carrying distinct prescriber profiles, referral hierarchies, and language preferences. A national thought leader in Delhi carries a different influence profile to one anchored in Chennai’s teaching hospital network or Pune’s oncology centres. Agencies applying uniform engagement models across this landscape lose the precision that determines prescriber uptake at launch.
India’s regulatory framework adds further complexity. The DCGI (Drugs Controller General of India) approval pathway — and evolving guidance from CDSCO (Central Drugs Standard Control Organisation) — means scientific communications must carry local regulatory alignment from day one. Agencies that build compliant medical education content in parallel with global timelines consistently outperform those that localise materials after regulatory clearance.
A medical communications agency operates under a distinct mandate from a pharma marketing agency focused on promotional brand communication. It requires MLR (Medical-Legal-Regulatory)-defensible scientific content, documented HCP interaction protocols aligned to MCI (Medical Council of India) guidelines, and engagement strategies built around OPPI (Organisation of Pharmaceutical Producers of India) Code requirements. OneAlphaMed quantifies this distinction before a single rupee of agency fees is committed.
The pharma brand strategy layer introduces a third consideration. When scientific communication and brand promotion operate through separate agencies without a shared strategic framework, the prescriber receives fragmented messaging. OneAlphaMed connects medical communications and pharma brand strategy within a single commercial logic — because in India’s market, disconnected execution is the most common cause of launch underperformance.
"Agencies with indication-specific KOL maps and DCGI-aligned content workflows consistently report faster time-to-prescriber at launch than those adapting global materials after regulatory clearance."
The most important capability question when evaluating a medical communications agency is not what therapy areas they have worked in — it is how deep they have gone. Generalist agencies accumulate credits across oncology and cardiology without building genuine scientific depth. Depth matters because HCP conversations that move prescribing decisions require a team that understands mechanism of action and competitive clinical positioning.
Request therapy-area-specific work samples rather than credentials pages. Probe for three things specifically: Published scientific content authored by the agency’s own staff, a named Medical Director with credentials in your indication, and a deep familiarity with the competitive landscape — including key clinical objections and payer questions by geography.
OneAlphaMed evaluates whether the scientific and commercial teams operate within a shared launch framework. A medical communications agency that cannot connect its scientific narrative to the commercial positioning brief produces content without commercial direction.
KOL network claims are often overstated. The differentiating question is whether that network is active, tiered, and indication-matched to your specific launch. A verified network must demonstrate tiered mapping to your launch geographies and active engagement in recent advisory boards or congress faculty roles.
Ask agencies to walk through their KOL mapping methodology. Strong agencies use peer-citation analysis and prescriber influence data rather than simple contact lists. Furthermore, evaluate activation infrastructure — advisory boards, CME events, and publication planning. A relationship without activation is a contact, not an asset.
Building your launch KOL and medical communications strategy?
Explore OneAlphaMed’s Brand Strategy & Launch capabilities →Understanding how KOL and Digital Opinion Leader strategies work in parallel? Read: KOL vs DOL in Pharma: The Rise of Digital Opinion Leaders
Compliance architecture is the single most reliable predictor of whether a product launch runs on-time. Timeline slippage in Indian pharma is most commonly traced to agencies that lack the internal MLR infrastructure to produce compliant content at the pace a launch demands.
Agencies must anchor their content architecture to MCI guidelines, OPPI Code requirements, and CDSCO norms from the first brief. OneAlphaMed includes MLR performance data as a standard criterion in every agency evaluation scorecard, testing the agency’s ability to manage scientific and promotional content streams simultaneously without creating bottlenecks.
The most decisive evaluation step is a structured scenario exercise. Provide the agency with a brief including your indication, launch window, and one genuine strategic challenge. Ask them to present their approach within ten working days.
Selecting a medical communications agency in India is a strategic decision, not a procurement exercise. The agencies that deliver measurable outcomes hold genuine therapy area depth, active KOL networks, and robust compliance frameworks. OneAlphaMed helps global and regional pharma brands bridge pharma brand strategy and scientific communication — ensuring that what your KOLs say and what your brand delivers reach the prescriber as a coherent message.
The evaluation framework matters as much as the final selection. Companies that run structured assessments before signing consistently report faster content approvals and better KOL engagement at launch. OneAlphaMed’s engagement model is built for the full continuum — from scientific narrative through commercial execution.
OneAlphaMed helps pharma and life sciences brands build medical communications and pharma brand strategy that work together. Explore our Brand Strategy & Launch services →
Evaluate four capabilities in order: therapy area scientific depth in your specific indication, KOL network quality and activation track record, compliance architecture (MLR process, MCI and OPPI Code alignment), and demonstrated new drug launch strategy experience in the Indian regulatory context. OneAlphaMed's evaluation framework weights these criteria in sequence — credentials alone do not predict performance.
The distinction matters most at brief stage. A pharma marketing agency in India focuses on promotional brand communication, consumer-facing creative, and market access messaging. A medcomms agency specialises in the scientific and clinical communication layer — KOL engagement, CME design, publication planning, and medical education across the product lifecycle. Both may be required for launch, but their roles, output types, and compliance obligations are distinct. OneAlphaMed advises on which combination each launch actually needs.
It is one of the two most decisive evaluation criteria, alongside therapy area expertise. An active, tiered KOL network matched to your indication and geography determines how quickly your scientific narrative reaches key prescribers. Ask for evidence of recent KOL activation — advisory board participation, congress faculty roles, CME authorship. A contact list is not a network.
Agencies operating in India should demonstrate operational alignment with MCI guidelines on HCP engagement, the OPPI Code of Pharmaceutical Marketing Practices, and CDSCO norms for scientific communication. They must operate a documented MLR review process with defined timelines, named reviewers, and archiving protocols. Verify that digital content carries the same compliance rigour as printed materials. OneAlphaMed includes this compliance audit as a standard step in every agency selection engagement.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.
